BALB/c鼠口服免疫猪水肿病大肠杆菌基因突变菌株的免疫效果

为了研究猪水肿病(ED)大肠杆菌SLT-Ⅱe基因突变菌株作为口服疫苗的免疫效果,本实验用已构建的猪ED大肠杆菌SLT-Ⅱe基因突变菌株口服免疫BALB/c小鼠,检测其血清中的IgG抗体及粪便和肠黏液中的slgA抗体水平,并进行淋巴细胞增殖检测及攻毒保护实验.结果表明该基因突变菌株具有良好的免疫性,能诱导小鼠体内产生IgG和sIgA抗体,并且能引起T淋巴细胞增殖反应.攻毒保护实验结果显示,口服免疫突变菌株能对小鼠提供良好的保护,保护率为75%(15/20).本研究结果证明,该大肠杆菌基因突变菌株在小鼠体内能激发体液免疫和细胞免疫反应,可作为猪ED口服疫苗的候选菌株.

Oral immune efficacy of an Escherichia coli mutant strain against Edema disease in swine

To investigate the protection efficacy of Escherichia coil SLT-Ⅱe gene mutant strain against Edema disease in swine, BALB/c mice were immunized orally with E.coli SLT-Ⅱe gene mutant strain and the immune protection rate in Kunming mice were examined, IgG level in the serum, sIgA level in fecal material and intestine mucus of the immunized mice were detected by ELISA, and the T lymphocyte proliferative response was also evaluated. The results showed that the E.coli mutant strain could induce humoral and mucosal immunity and provoked proliferative response of the T lymphocyte. It provided 75 % (15/20) protection to the mice after challenged intraperitoneally with Shiga-like toxinⅡvariant. These results supported the E.coli mutant as a potential oral vaccine candidate against the Edema disease in swine.